NADPH-oxidase Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S7171	Setanaxib (GKT137831)	Setanaxib (GKT137831, GKT831) is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. This compound suppresses reactive oxygen species (ROS) production and partly inhibits ferroptosis.	Immunity, 2025, S1074-7613(25)00069-X Int J Biol Sci, 2025, 21(5):2313-2329 Immunity, 2024, 57(1):52-67.e10
S8639	DPI (Diphenyleneiodonium chloride)	Diphenyleneiodonium chloride (DPI) is an inhibitor of NADPH oxidase and also a potent, irreversible, and time-, temperature-dependent iNOS/eNOS inhibitor. It also functions as a TRPA1 activator and selectively inhibits intracellular reactive oxygen species (ROS).	Redox Biol, 2025, 80:103485 Sci Adv, 2025, 11(34):eadv6937 Exp Mol Med, 2024, 56(12):2602-2616
S2425	Apocynin	Apocynin is a selective NADPH-oxidase inhibitor with IC50 of 10 μM.	Cell Death Discov, 2025, 11(1):458 Cell Signal, 2025, 128:111630 Antioxidants (Basel), 2023, 12(1)145
S5304	2-Acetylphenothiazine (ML171)	2-Acetylphenothiazine (ML171, 2-APT) is a potent and selective inhibitor of NADPH-oxidase, with IC50s of 0.25 μM, 5 μM, 3μM, 5 μM and 5.5 μM for NOX1, NOX2, NOX3, NOX4 and xanthine oxidase, respectively.	American Journal of Respiratory and Critical Care Medicine, June 1, 2023, 1486-1497 Front Plant Sci, 2024, 15:1418049 American Journal of Respiratory and Critical Care Medicine, 2023, 1486-1497
S6656	VAS2870	VAS2870 is a pan-NADPH oxidase (NOX) inhibitor.	Front Oncol, 2024, 14:1438306 Frontiers in Oncology, 2024, 1438306 J Nanobiotechnology, 2023, 21(1):117
S0178	GLX351322	GLX351322 is a NADPH oxidase 4 (NOX4) inhibitor. This compound inhibits hydrogen peroxide production from tetracycline inducible NOX4-overexpressing cells with IC50 of 5 μM.	Cell Commun Signal, 2024, 22(1):393 Cell Commun Signal, 2024, 22(1):393. Biomed Pharmacother, 2023, 165:115052
S8974	GSK2795039	GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) with pIC50 of 6.57 for NOX2-mediated activation of HRP/Amplex Red. This compound inhibits reactive oxygen species (ROS) production, NADPH consumption and reduces apoptosis.	Phytomedicine, 2024, 136:156283 Open Med (Wars), 2024, 19(1):20240898 Int J Mol Sci, 2023, 24(18)14369
S0777	Isuzinaxib (APX-115 free base)	Isuzinaxib (APX-115 free base, Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. This compound significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.	American Journal of Physiology-Renal Physiology, 2024, F202-F218
S4299	Dicoumarol	Dicoumarol is a competitive NADPH quinone oxidoreductase (NQO1) inhibitor,and used as an anticoagulant by interfering with the metabolism of vitamin K.	Adv Sci (Weinh), 2025, 12(7):e2411538 Redox Biol, 2024, 75:103292 Redox Biology, 2024, 103292
S1907	Metronidazole	Metronidazole, a synthetic antibacterial and antiprotozoal agent of the nitroimidazole class, is used against protozoa.	Dis Model Mech, 2024, 17(10)dmm050900 Microorganisms, 2022, 10(7)1421 Elife, 2021, 10e69795
S5703	Carvedilol Phosphate	Carvedilol Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimetic activity.	Res Pharm Sci, 2016, 11(5):419-427 Res Pharm Sci, 2015, 10(5):388-96
S9617	G6PDi-1	G6PDi-1 is an effective inhibitor of glucose-6-phosphate dehydrogenase (G6PD). This compound depletes NADPH and decreases inflammatory cytokine production.	EMBO J, 2023, e110620. The EMBO Journal, 2023, e110620
S6749	ASP-9521	ASP-9521 is a selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17β-HSD5), also known as aldo-keto reductase family 1 member C3 (AKR1C3).
S0764	AKR1C1-IN-1	AKR1C1-IN-1 is a potent and selective inhibitor of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) with Ki of 4 nM, 87 nM, 4.2 μM and 18.2 μM for AKR1C1, AKR1C2, AKR1C3 and AKR1C4, respectively.
S0468	AKR1C3-IN-1	AKR1C3-IN-1 is a highly potent inhibitor of aldo-keto reductaseAKR1C3 with an IC50 of 13 nM. It can be used in research targeting both breast and prostate cancer.